Know Cancer

forgot password

Randomized Phase II Trial Evaluating the Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Wild Type KRAS Colorectal Cancer

Phase 2
18 Years
75 Years
Not Enrolling
Colorectal Cancer Metastatic, Liver Metastases, KRAS Wild Type Colorectal Cancer

Thank you

Trial Information

Randomized Phase II Trial Evaluating the Efficacy of FOLFOX Alone, FOLFOX Plus Bevacizumab and FOLFOX Plus Panitumumab as Perioperative Treatment in Patients With Resectable Liver Metastases From Wild Type KRAS Colorectal Cancer

Inclusion Criteria:

- Histologically proven CRC with 1 to 8 metachronous or synchronous liver metastases
considered to be completely resectable.

- Primary tumor (or liver metastasis) of CRC must be KRAS status "wild type".

- Patients must have undergone complete resection (R0) of the primary tumor at least 4
weeks before randomization. Or for patients with synchronous metastases the primary
tumor can be resected (R0) at the same time as the liver metastases if: the patient
has a non-obstructive primary tumor and is able to receive preoperative chemotherapy
(3-4 months) before surgery.

- Measurable hepatic disease by RECIST version 1.1.

- Patients must be 18 years old or older.

- A WHO performance status of 0 or 1. Radiotherapy alone is allowed if given pre or
post protocol treatment.

- Previous adjuvant chemotherapy for primary CRC is allowed if completed at least 12
months before inclusion in this study.

- All the following tests should be done within 4 weeks prior to randomization:

- Absolute neutrophil count ≥ 1.5 x 109/L, platelets ≥ 100 x 109/L, hemoglobin ≥ 9 g/dL
and white blood cell count (WBC) ≥ 3 x 109/L.

- Serum creatinine ≤ 1.5 times the upper limit of normal (ULN) (to exclude severe renal
impairment); no significant proteinuria (urine protein < 1g/24 hours urine
collection) OR urine protein/creatinine ratio < 1.0 OR 1+ proteinuria on urine

- Absence of major hepatic insufficiency (bilirubin ≤ 1.5 x ULN and aspartate
aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤ 5 x ULN).

- Magnesium ≥ lower limit of normal (LLN)

- Patients with a buffer range from the normal values of +/- 5% for hematology and +/-
10% for biochemistry are acceptable. This will not apply for Renal Function,
including Creatinine.

- Women of child bearing potential (WOCBP) must have a negative serum (or urine)
pregnancy test within 14 days prior to the first dose of study treatment.

- Patients of childbearing / reproductive potential should use adequate birth control
measures, as defined by the investigator, during the study treatment period and for
at least 6 months after the last study treatment. A highly effective method of birth
control is defined as those which result in low failure rate (i.e. less than 1% per
year) when used consistently and correctly.

- Female subjects who are breast feeding should discontinue nursing prior to the first
dose of study treatment and until 6 months after the last study treatment.

- Before patient registration/randomization, written informed consent must be given
according to ICH/GCP, and national/local regulations.

Exclusion Criteria:

- Evidence of extra-hepatic metastasis (of CRC).

- Previous chemotherapy for metastatic disease or surgical treatment (e.g. surgical
resection or radiofrequency ablation) for liver metastasis.

- Previous exposure to EGFR or VEGF/VEGFR targeting therapy within the last 12 months.

- Major surgical procedure, open biopsy, or significant traumatic injury within 4 weeks
prior to randomization.

- Regular use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).

- Bleeding diathesis (e.g. hemoptysis of ≥ 1/2 teaspoon or 2.5mL), coagulopathy, or
need for administration of full-dose anti-coagulant(s).

- Clinically significant cardiovascular disease, including: uncontrolled hypertension,
New York Heart Association (NYHA) class II-IV heart failure, myocardial infarction or
unstable angina pectoris, cerebrovascular accident or transient ischemic attack
within the past 12 months, peripheral vascular disease ≥ grade 2, serious cardiac
arrhythmia requiring medication and other clinically significant cardiovascular

- Peripheral neuropathy > grade 1 (Common Terminology Criteria for Adverse Events,
v4.0) serious wound complications, ulcers, or bone fractures.

- Symptomatic diverticulitis or active or uncontrolled gastroduodenal ulceration.

- History or evidence of interstitial lung disease (e.g. pneumonitis, pulmonary

- Significant disease that, in the investigator's opinion, would exclude the patient
from the study. Including known allergy or any other adverse reaction to any of the
study drugs (including any of the excipients) or to any related compound, including
hypersensitivity to Chinese hamster ovary (CHO) cell products or other recombinant
human or humanized antibodies.

- Presence of any psychological, familial, sociological, or geographical condition
potentially hampering compliance with the study protocol and follow-up schedule;
those conditions should be discussed with the patient before registration in the

- Participation in another clinical study (except sub studies of this protocol) within
the 30 days before randomization and during this study.

Type of Study:


Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression free survival

Outcome Description:

Increase in progression free survival rate at 1 year in each experimental arm (mFOLFOX6 + bevacizumab or panitumumab) compared to mFOLFOX6 alone arm.

Outcome Time Frame:

1 year

Safety Issue:


Principal Investigator

Bernard Nordlinger, Pr.

Investigator Role:

Study Chair

Investigator Affiliation:

C.H.U. AMBROISE PARE AP-HP, Boulogne-Billancourt, France


Austria: Agency for Health and Food Safety

Study ID:




Start Date:

October 2012

Completion Date:

October 2016

Related Keywords:

  • Colorectal Cancer Metastatic
  • Liver Metastases
  • KRAS Wild Type Colorectal Cancer
  • Liver metastases
  • Colorectal Cancer
  • KRAS wild type
  • Bevacizumab
  • Panitumumab
  • Randomized
  • Phase II
  • Perioperative treatment
  • Adjuvant
  • Neo-adjuvant
  • Surgery
  • Progression Free Survival
  • Colorectal Neoplasms
  • Neoplasm Metastasis
  • Neoplasms, Second Primary
  • Neoplasms
  • Liver Neoplasms